Practically 60% of sufferers with IgAN within the SPARTAN Examine achieved full remission when utilizing FILSPARI as first-line therapy

SPARTACUS Examine, PROTECT open-label extension, and real-world proof shows spotlight preliminary security and efficacy information of FILSPARI together therapy in IgAN

Late-breaking presentation demonstrates sparsentan delivered speedy and sustained proteinuria discount, and long-term kidney well being advantages in a subset of sufferers with genetic, usually therapy resistant, FSGS

SAN DIEGO, Oct. 26, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc.,  (Nasdaq: TVTX), introduced new information additional demonstrating the scientific advantage of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforcing its potential in focal segmental glomerulosclerosis (FSGS) on the American Society of Nephrology (ASN) Kidney Week  2024.

The information introduced at ASN offered extra proof that FILSPARI is efficient throughout all subgroups of IgAN sufferers studied to-date, and that it achieved important ranges of full remission when utilized in newly identified sufferers. We additionally shared preliminary information exhibiting that FILSPARI safely induced additional proteinuria discount when used with SGLT2 inhibitors or steroids, supportive of the flexibleness for use together with different medicines as wanted, stated Jula Inrig, M.D., chief medical officer of Travere Therapeutics. Moreover, we shared information exploring a subgroup of genetic FSGS sufferers in our DUPLEX Examine. Genetic FSGS sufferers are sometimes therapy resistant so the numerous reductions in proteinuria and profit on outcomes reported on this group are very encouraging.

Key Findings from the PROTECT Examine Subgroup Evaluation of Sufferers with Proteinuria Above and Beneath 1 g/g

• FILSPARI delivered superior proteinuria discount, and full proteinuria remission earlier and extra often in comparison with irbesartan no matter baseline UPCR, together with these at lower than 1.0 g/g.

Key Findings from the SPARTAN Examine Evaluating FILSPARI as a First-Line Remedy

• FILSPARI delivered a speedy and sustained discount in proteinuria of roughly 70% from baseline over 24 weeks in newly identified, RASi-naïve sufferers, and practically 60% of sufferers within the SPARTAN examine achieved full remission of proteinuria at any cut-off date through the therapy interval. All through the 24 weeks, estimated glomerular filtration charge was steady.

Key Findings from the SPARTACUS Examine, PROTECT OLE and Actual-World Use Evaluating FILSPARI in Mixture Remedy for IgAN

• Interim information from the SPARTACUS Examine demonstrated that FILSPARI, when added to steady SGLT2i, was usually effectively tolerated. Roughly one-third of sufferers had their proteinuria lowered by not less than 50%, and two-thirds of sufferers by not less than 30% when measured after 24 weeks of therapy.
• Information from the continuing PROTECT Examine open-label extension and real-world use confirmed favorable security and additive efficacy outcomes when SGLT2i or immunosuppressants had been mixed with foundational FILSPARI therapy.

Key Findings from the DUPLEX Examine Evaluating Sparsentan in Focal Segmental Glomerulosclerosis

• In a late-breaking presentation from the DUPLEX Examine in a subset of sufferers with genetic mutations in podocyte proteins, a high-risk, therapy resistant FSGS, sparsentan delivered a speedy and sustained proteinuria discount, together with some sufferers who achieved full remission and long-term kidney well being advantages.
• An analysis of patient-reported outcomes from 306 grownup sufferers within the DUPLEX Examine confirmed that health-related high quality of life for these sufferers with FSGS on sparsentan was steady over the two-year therapy interval, and that sufferers’ burden of kidney illness was improved in comparison with these receiving irbesartan.

Key Findings from the EPPIK Examine Evaluating Sparsentan in Uncommon Proteinuric Illness in Pediatric Sufferers

• Preliminary information from the EPPIK Examine confirmed that youngsters with a spread of uncommon proteinuric glomerular illness handled with sparsentan skilled speedy and strong proteinuria discount of roughly 50% over 12 weeks.

About IgA Nephropathy

IgA nephropathy (IgAN), additionally referred to as Berger’s illness, is a uncommon progressive kidney illness characterised by the buildup of immunoglobulin A (IgA), a protein that helps the physique struggle infections, within the kidneys. The deposits of IgA trigger a breakdown of the traditional filtering mechanisms within the kidney, resulting in blood within the urine (hematuria), protein within the urine (proteinuria) and a progressive lack of kidney operate. Different signs of IgAN could embody swelling (edema) and hypertension.

IgAN is the most typical sort of major glomerulonephritis worldwide and a number one reason for kidney failure on account of glomerular illness. IgAN is estimated to have an effect on up to 150,000 folks within the  U.S.  and is among the commonest glomerular illnesses in  Europe  and  Japan.

About Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS) is a uncommon proteinuric kidney dysfunction in each youngsters and adults that’s estimated to have an effect on greater than 40,000 sufferers within the US with comparable prevalence in  Europe. The dysfunction is outlined by progressive scarring of the kidney and sometimes results in kidney failure. FSGS is characterised by proteinuria, the place protein leaks into the urine on account of a breakdown of the traditional filtration mechanism within the kidney. As soon as within the urine, protein is taken into account to be poisonous to different elements of the kidney, particularly the tubules, and is believed to contribute to additional illness development. Different widespread signs embody swelling in elements of the physique, often known as edema, in addition to low blood albumin ranges, irregular lipid profiles and hypertension. Sparsentan shouldn’t be authorised to be used in FSGS. There may be at present no authorised pharmacologic indicated for the therapy of FSGS.

About  Travere Therapeutics

At  Travere Therapeutics, we’re in uncommon for all times. We’re a biopharmaceutical firm that comes collectively on daily basis to assist sufferers, households and caregivers of all backgrounds as they navigate life with a uncommon illness. On this path, we all know the necessity for therapy choices is pressing “ that’s the reason our world crew works with the uncommon illness neighborhood to establish, develop and ship life-changing therapies. In pursuit of this mission, we repeatedly search to grasp the varied views of uncommon sufferers and to courageously forge new paths to make a distinction of their lives and supply hope “ right now and tomorrow. For extra info, go to  travere.com

FILSPARI ^® (sparsentan)  U.S.  Indication

FILSPARI  (sparsentan) is indicated to sluggish kidney operate decline in adults with major immunoglobulin A nephropathy (IgAN) who’re in danger for illness development.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: HEPATOTOXICITY AND EMBRYO-FETAL TOXICITY

Due to the dangers of hepatotoxicity and beginning defects, FILSPARI is accessible solely by a restricted program referred to as the FILSPARI REMS. Underneath the FILSPARI REMS, prescribers, sufferers and pharmacies should enroll in this system.

Hepatotoxicity

Some Endothelin Receptor Antagonists (ERAs) have brought on elevations of aminotransferases, hepatotoxicity, and liver failure. In scientific research, elevations in aminotransferases (ALT or AST) of not less than 3-times the Higher Restrict of Regular (ULN) have been noticed in up to three.5% of FILSPARI-treated sufferers, together with instances confirmed with rechallenge.

Measure transaminases and bilirubin earlier than initiating therapy and month-to-month for the primary 12 months, after which each 3 months throughout therapy. Interrupt therapy and carefully monitor sufferers who develop aminotransferase elevations greater than 3x ULN.

FILSPARI ought to usually be prevented in sufferers with elevated aminotransferases (>3x ULN) at baseline as a result of monitoring for hepatotoxicity could also be tougher and these sufferers could also be at elevated danger for critical hepatotoxicity.

Embryo-Fetal Toxicity

FILSPARI may cause main beginning defects if utilized by pregnant sufferers based mostly on animal information. Subsequently, being pregnant testing is required earlier than the initiation of therapy, throughout therapy and one month after discontinuation of therapy with FILSPARI. Sufferers who can develop into pregnant should use efficient contraception earlier than the initiation of therapy, throughout therapy, and for one month after discontinuation of therapy with FILSPARI.

Contraindications

FILSPARI is contraindicated in sufferers who’re pregnant. Don’t coadminister FILSPARI with angiotensin receptor blockers (ARBs), ERAs, or aliskiren.

Warnings and Precautions

• Hepatotoxicity:  Elevations in ALT or AST of not less than 3-fold ULN have been noticed in up to three.5% of FILSPARI-treated sufferers, together with instances confirmed with rechallenge. Whereas no concurrent elevations in bilirubin >2-times ULN or instances of liver failure had been noticed in FILSPARI-treated sufferers, some ERAs have brought on elevations of aminotransferases, hepatotoxicity, and liver failure. To cut back the danger of potential critical hepatotoxicity, measure serum aminotransferase ranges and complete bilirubin previous to initiation of therapy and month-to-month for the primary  12 months, then each  3 months  throughout therapy.

Advise sufferers with signs suggesting hepatotoxicity (nausea, vomiting, proper higher quadrant ache, fatigue, anorexia, jaundice, darkish urine, fever, or itching) to right away cease therapy with FILSPARI and search medical consideration. If aminotransferase ranges are irregular at any time throughout therapy, interrupt FILSPARI and monitor as really useful.

Take into account re-initiation of FILSPARI solely when hepatic enzyme ranges and bilirubin return to pretreatment values and solely in sufferers who haven’t skilled scientific signs of hepatotoxicity. Keep away from initiation of FILSPARI in sufferers with elevated aminotransferases (>3x ULN) previous to drug initiation as a result of monitoring hepatotoxicity in these sufferers could also be tougher and these sufferers could also be at elevated danger for critical hepatotoxicity.

• Embryo-Fetal Toxicity:  FILSPARI may cause fetal hurt when administered to a pregnant affected person and is contraindicated throughout being pregnant. Advise sufferers who can develop into pregnant of the potential danger to a fetus. Acquire a being pregnant take a look at previous to initiation of therapy with FILSPARI, month-to-month throughout therapy, and one month after discontinuation of therapy. Advise sufferers who can develop into pregnant to make use of efficient contraception previous to initiation of therapy, throughout therapy, and for one month after discontinuation of therapy with FILSPARI.
• FILSPARI REMS:   Because of the danger of hepatotoxicity and embryo-fetal toxicity, FILSPARI is accessible solely by a restricted program referred to as the FILSPARI REMS. Prescribers, sufferers, and pharmacies have to be enrolled within the REMS program and adjust to all necessities (www.filsparirems.com).
• Hypotension:  Hypotension has been noticed in sufferers handled with ARBs and ERAs. There was a larger incidence of hypotension-associated hostile occasions, some critical, together with dizziness, in sufferers handled with FILSPARI in comparison with irbesartan. In sufferers in danger for hypotension, take into account eliminating or adjusting different antihypertensive medicines and sustaining applicable quantity standing. If hypotension develops, regardless of elimination or discount of different antihypertensive medicines, take into account a dose discount or dose interruption of FILSPARI. A transient hypotensive response shouldn’t be a contraindication to additional dosing of FILSPARI, which may be given as soon as blood strain has stabilized.
• Acute Kidney Harm:  Monitor kidney operate periodically. Medicine that inhibit the renin-angiotensin system (RAS) may cause kidney damage. Sufferers whose kidney operate could rely partially on the exercise of the RAS (e.g., sufferers with renal artery stenosis, persistent kidney illness, extreme congestive coronary heart failure, or quantity depletion) could also be at specific danger of creating acute kidney damage on FILSPARI. Take into account withholding or discontinuing remedy in sufferers who develop a clinically important lower in kidney operate whereas on FILSPARI.
• Hyperkalemia:  Monitor serum potassium periodically and deal with appropriately. Sufferers with superior kidney illness, taking concomitant potassium-increasing medicine (e.g., potassium dietary supplements, potassium-sparing diuretics), or utilizing potassium-containing salt substitutes are at elevated danger for creating hyperkalemia. Dosage discount or discontinuation of FILSPARI could also be required.
• Fluid Retention:  Fluid retention could happen with ERAs, and has been noticed in scientific research with FILSPARI. FILSPARI has not been evaluated in sufferers with coronary heart failure. If clinically important fluid retention develops, consider the affected person to find out the trigger and the potential must provoke or modify the dose of diuretic therapy then take into account modifying the dose of FILSPARI.

Commonest hostile reactions

The most typical hostile reactions ( ‰¥5%) are hyperkalemia, hypotension (together with orthostatic hypotension), peripheral edema, dizziness, anemia, and acute kidney damage.

Drug interactions

• Renin-Angiotensin System (RAS) Inhibitors and ERAs:  Don’t coadminister FILSPARI with ARBs, ERAs, or aliskiren on account of elevated dangers of hypotension, syncope, hyperkalemia, and adjustments in renal operate (together with acute renal failure).
• Sturdy and Reasonable CYP3A Inhibitors:  Keep away from concomitant use of FILSPARI with sturdy CYP3A inhibitors. If a powerful CYP3A inhibitor can’t be prevented, interrupt FILSPARI therapy. When resuming therapy with FILSPARI, take into account dose titration. Monitor blood strain, serum potassium, edema, and kidney operate recurrently when used concomitantly with average CYP3A inhibitors. Concomitant use with a powerful CYP3A inhibitor will increase sparsentan publicity which can improve the danger of FILSPARI hostile reactions.
• Sturdy CYP3A Inducers:  Keep away from concomitant use with a powerful CYP3A inducer. Concomitant use with a powerful CYP3A inducer decreases sparsentan publicity which can scale back FILSPARI efficacy.
• Antacids and Acid Decreasing Brokers:  Administer FILSPARI 2 hours earlier than or after administration of antacids. Keep away from concomitant use of acid lowering brokers (histamine H2 receptor antagonist and PPI proton pump inhibitor) with FILSPARI. Sparsentan reveals pH-dependent solubility. Antacids or acid lowering brokers could lower sparsentan publicity which can scale back FILSPARI efficacy.
• Non-Steroidal Anti-Inflammatory Brokers (NSAIDs), Together with Selective Cyclooxygenase-2 (COX-2) Inhibitors:  Monitor for indicators of worsening renal operate with concomitant use with NSAIDs (together with selective COX-2 inhibitors). In sufferers with quantity depletion (together with these on diuretic remedy) or with impaired kidney operate, concomitant use of NSAIDs (together with selective COX-2 inhibitors) with medicine that antagonize the angiotensin II receptor could end in deterioration of kidney operate, together with doable kidney failure.
• CYP2B6, 2C9, and 2C19 Substrates:  Monitor for efficacy of concurrently administered CYP2B6, 2C9, and 2C19 substrates and take into account dosage adjustment in accordance with the Prescribing Info. Sparsentan decreases publicity of those substrates, which can scale back efficacy associated to those substrates.
• P-gp and BCRP Substrates:  Keep away from concomitant use of delicate substrates of P-gp and BCRP with FILSPARI. Sparsentan could improve publicity of those transporter substrates, which can improve the danger of hostile reactions associated to those substrates.
• Brokers Rising Serum Potassium:  Monitor serum potassium often in sufferers handled with FILSPARI and different brokers that improve serum potassium. Concomitant use of FILSPARI with potassium-sparing diuretics, potassium dietary supplements, potassium-containing salt substitutes, or different medicine that elevate serum potassium ranges could end in hyperkalemia.

Please see the complete  Prescribing Info, together with BOXED WARNING, for extra Essential Security Info.

Ahead Trying Statements
This press release comprises forward-looking statements as that time period is outlined within the Non-public Securities Litigation Reform Act of 1995. With out limiting the foregoing, these statements are sometimes recognized by the phrases on-track, positioned, stay up for, will, would, could, may, believes, anticipates, plans, expects, intends, potential, or comparable expressions. As well as, expressions of methods, intentions or plans are additionally forward-looking statements. Such forward-looking statements embody, however are usually not restricted to, references to: assertion associated to the potential for FILSPARI for use as a first-line therapy for IgAN and the flexibleness of FILSPARI for use together with different medicines; statements regarding scientific research, together with however not restricted to trial design, outcomes and timing associated thereto; and prevalence estimates. Such forward-looking statements are based mostly on present expectations and contain inherent dangers and uncertainties, together with elements that would delay, divert or change any of them, and will trigger precise outcomes and outcomes to vary materially from present expectations. No forward-looking assertion may be assured. Among the many elements that would trigger precise outcomes to vary materially from these indicated within the forward-looking statements are dangers associated to the timing and consequence of the research described herein and uncertainties related to the regulatory assessment and approval course of, in addition to dangers and uncertainties related to enrollment of scientific trials for uncommon illnesses, and dangers that ongoing or deliberate scientific trials could not succeed or could also be delayed for security, regulatory or different causes. The Firm additionally faces dangers associated to its enterprise and funds generally, the success of its business merchandise and dangers and uncertainties related to its preclinical and scientific stage pipeline. Particularly, the Firm faces dangers related to the continuing business launch of FILSPARI, market acceptance of its business merchandise together with efficacy, security, price, reimbursement, and profit over competing therapies, in addition to dangers related to the profitable growth and execution of business methods for such merchandise, together with FILSPARI. The dangers and uncertainties the Firm faces with respect to its preclinical and scientific stage pipeline embody danger that the Firm’s scientific candidates is not going to be discovered to be protected or efficient and that present or anticipated future scientific trials is not going to proceed as deliberate. There isn’t any assure that regulators will grant approval of sparsentan for FSGS. The Firm additionally faces the danger that it will likely be unable to boost extra funding which may be required to finish growth of all or any of its product candidates, together with because of macroeconomic situations; dangers regarding the Firm’s dependence on contractors for scientific drug provide and business manufacturing; uncertainties regarding patent safety and exclusivity durations and mental property rights of third events; dangers related to regulatory interactions; and dangers and uncertainties regarding aggressive merchandise, together with present and potential future generic competitors with sure of the Firm’s merchandise, and technological adjustments that will restrict demand for the Firm’s merchandise. The Firm additionally faces extra dangers related to world and macroeconomic situations, together with well being epidemics and pandemics, together with dangers associated to potential disruptions to scientific trials, commercialization exercise, provide chain, and manufacturing operations. You might be cautioned to not place undue reliance on these forward-looking statements as there are necessary elements that would trigger precise outcomes to vary materially from these in forward-looking statements, a lot of that are past our management. The Firm undertakes no obligation to publicly replace any forward-looking assertion, whether or not because of new info, future occasions, or in any other case. Traders are referred to the complete dialogue of dangers and uncertainties, together with underneath the heading Danger Elements, as included within the Firm’s most up-to-date Kind 10-Okay, Kind 10-Q and different filings with the Securities and Alternate Fee.

Contact Information